Precision diagnostics company Proteomics International Laboratories (ASX:PIQ) has announced the successful development and release of the next generation of the PromarkerD test system.
The system provides a simplified, immunoassay-based diagnostic that accurately predicts kidney function decline in adults with type 2 diabetes (T2D).
The company stated that the results presented over the weekend at the 85th Scientific Sessions of the American Diabetes Association demonstrate that this technology builds upon its proven clinical utility and represents an advancement toward large-scale clinical deployment in pathology laboratories globally.
Diabetes-related chronic kidney disease (DKD) is a significant global health burden.
Proteomics said the PromarkerD test can identify individuals at risk of DKD up to four years before clinical symptoms appear. It said the early identification enables targeted, preventative care to reduce progression to costly and life-threatening end-stage renal disease requiring dialysis or kidney transplant.
The test now measures two plasma protein biomarkers (ApoA4 and CD5L) alongside age and estimated glomerular filtration rate (eGFR) to generate a personalised DKD risk score.
Proteomics said the new PromarkerD matched previously published performance, and identified 86 per cent of at-risk individuals, all missed by the current standard-of-care eGFR and urinary albumin:creatinine ratio test.